“Two vaccines are better than one,” says Tara Lachapelle on Bloomberg. This week brought positive news about trials of Moderna’s vaccine for Covid-19. The update gave global markets a profitable start to the week, with America’s S&P 500 and the MSCI World Index both hitting record highs on Monday. The FTSE 100 rose to its highest level since June and has gained more than 13% so far this month.
A global bull market
The rally took a break the following day but, arguably, markets should be even more upbeat, says Nils Pratley in The Guardian. The Moderna vaccine is easier to store and transport than the Pfizer jab that made the headlines last week.
That could speed up the daunting logistical challenges of rollout. For “airlines, events and hospitality… it really matters whether a vaccination programme takes six months, a year or more”.
Try 6 free issues of MoneyWeek today
Get unparalleled financial insight, analysis and expert opinion you can profit from.
Start your trial
Sign up for MoneyWeek’s free twice-daily newsletter.
Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
The bulls are out in force. Last week’s vaccine news triggered a $44.5bn flood of inflows into global stock funds, say Eric Platt and David Carnevali in the Financial Times. That is the biggest weekly inflow in “at least two decades”.
Latest Videos FromMoneyWeek
American bulls are not finding many bargains, though. On a cyclically adjusted price/earnings ratio (Cape) of 31.26 the US market is currently more expensive than it has been for 96% of the time since 1881, says Mark Hulbert for marketwatch.com.
No wonder, then, that new research from Kevin Lansing, an adviser at the Federal Reserve Bank of San Francisco, suggests that US stocks are poised to “barely outperform inflation” over the coming decade.
Value stocks will rise
The US stock rally is already showing “signs of exhaustion”, says Cormac Mullen on Bloomberg. The market’s heavy technology weighting helped the S&P 500 outperform most other major bourses this year through early September. Yet since then the US has underperformed the MSCI World Ex-USA Index by 4%. The baton has now passed to markets in Europe and Japan, which boast a bigger stable of value stocks (see page 20).
Since 2009 the MSCI USA Value Index has returned 246%, against 661% for the equivalent US growth index, says Jon Sindreu in The Wall Street Journal. Value seems due a catch-up rally, but history suggests that such periods don’t last very long. After their re-opening bounce, “old economy” shares are likely to face the same problems as before Covid-19: “ultra-low interest rates”, poor returns on equity and, for financial stocks, “strict banking regulation”.
Vaccine news could bring higher interest rates than the market expects, says the Financial Times. Eye-watering valuations are partly the result of years of easy central-bank money. Yet US ten-year Treasury bond yields have been ticking up of late, reflecting falling bond prices. This suggests greater confidence that growth will return and long-term interest rates will rise. “Lower-for-longer” interest rates may not stay low for quite so long after all.
